The CARAMEL project was recently recognised as the best research project at the XLV Congress of the Spanish Society of Family and Community Medicine (semFYC), marking a significant milestone in its mission to improve cardiovascular prevention for women in midlife.
Presented by Estibaliz Gamboa Moreno from Biogipuzkoa, along with co-authors Irene Alonso Sampedro, Luis Gabriel Luque Romero, Miguel Giráldez Álvarez, and Iván Macía Oliver, our Project Coordinator, the study entitled “Personalized cardiovascular prevention in perimenopausal women: a multimodal approach in primary care” showcased CARAMEL’s commitment to integrating cutting-edge AI with clinical practice.
The presentation focused on the urgent need to enhance cardiovascular risk prediction for women aged 40–60. The CARAMEL project responds with a multimodal, AI-driven strategy that includes:
- A mixed-method study involving over 7,500 women across Europe and Latin America, including nearly 3,000 from Spain;
- A retrospective study analysing real-world clinical data;
- A prospective observational study tracking 3,000 women (1,000 in Spain) over two years with data from wearables, imaging, and biomarkers;
- An interventional study testing the impact of personalized prevention strategies in real-world clinical settings.
These integrated efforts are aimed at redefining how cardiovascular risk is assessed and managed in primary care, with a strong emphasis on co-design, digital empowerment, and health equity. The Spanish cohort plays a central role, reflecting Spain’s leadership in clinical implementation within the CARAMEL consortium.
This recognition at semFYC underscores CARAMEL’s relevance and innovation, reaffirming its role in shaping the future of women’s heart health, where primary care serves not only as the first line of contact, but as a cornerstone for personalised, AI-supported prevention.
